Europe is home to 98 ‘MidPharmas’: companies that research, develop, and commercialise pharmaceutical products with €100m-€10bn annual revenue. In our 2024 European MidPharma report, we examine the 2023 performance of European-headquartered MidPharmas and contrast it to Big Pharma. We then explore the success drivers that enable MidPharmas to thrive.
What to Expect in the Report
This year’s report explores how the most successful MidPharmas are delivering growth and impressive returns through common success drivers:
-
- Establish a therapeutic area focus
-
- Prioritise R&D productivity
-
- Maintain profitable commercialisation
You can download your free copy of our 2024 report by clicking the button above.
